Cargando…

Computational Investigations on the Natural Small Molecule as an Inhibitor of Programmed Death Ligand 1 for Cancer Immunotherapy

Several therapeutic monoclonal antibodies approved by the FDA are available against the PD-1/PD-L1 (programmed death 1/programmed death ligand 1) immune checkpoint axis, which has been an unprecedented success in cancer treatment. However, existing therapeutics against PD-L1, including small molecul...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Geethu S, Moustafa, Mahmoud, Sahoo, Amaresh Kumar, Malý, Petr, Bharadwaj, Shiv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145275/
https://www.ncbi.nlm.nih.gov/pubmed/35629327
http://dx.doi.org/10.3390/life12050659